These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 21993867)
1. Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation--a 2-year follow-up on a withdrawal study. Hässler F; Glaser T; Reis O Pharmacopsychiatry; 2011 Nov; 44(7):339-43. PubMed ID: 21993867 [TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses. Hässler F; Glaser T; Pap AF; Beneke M; Diefenbacher A; Reis O; Pharmacopsychiatry; 2008 Nov; 41(6):232-9. PubMed ID: 19067260 [TBL] [Abstract][Full Text] [Related]
3. Treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol. Hässler F; Dück A; Jung M; Reis O J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):579-81. PubMed ID: 25514543 [TBL] [Abstract][Full Text] [Related]
4. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. Haessler F; Glaser T; Beneke M; Pap AF; Bodenschatz R; Reis O; Br J Psychiatry; 2007 May; 190():447-8. PubMed ID: 17470962 [TBL] [Abstract][Full Text] [Related]
5. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. Hovens JE; Dries PJ; Melman CT; Wapenaar RJ; Loonen AJ J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129 [TBL] [Abstract][Full Text] [Related]
6. Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later. Janowsky DS; Barnhill LJ; Khalid AS; Davis JM J Clin Psychiatry; 2006 Aug; 67(8):1272-7. PubMed ID: 16965207 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. Schwarz V; Reis O; Glaser T; Thome J; Hiemke C; Haessler F Pharmacopsychiatry; 2014 Jan; 47(1):29-32. PubMed ID: 24307207 [TBL] [Abstract][Full Text] [Related]
8. Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study. Fuglum E; Schillinger A; Andersen JB; Belstad BE; Jensen D; Müller F; Müller KJ; Schulstad B; Elgen K Pharmatherapeutica; 1989; 5(5):285-91. PubMed ID: 2568639 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Hässler F; Reis O Dev Disabil Res Rev; 2010; 16(3):265-72. PubMed ID: 20981765 [TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders. Singh I; Owino WJ J Intellect Disabil Res; 1992 Dec; 36 ( Pt 6)():541-9. PubMed ID: 1477491 [TBL] [Abstract][Full Text] [Related]
11. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study. Spivak B; Mozes T; Mester R; Kodelik M; Weizman A J Child Adolesc Psychopharmacol; 2001; 11(3):279-84. PubMed ID: 11642477 [TBL] [Abstract][Full Text] [Related]
12. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Chin CN; Hamid AR; Philip G; Ramlee T; Mahmud M; Zulkifli G; Loh CC; Zakariah MS; Norhamidah MS; Suraya Y; Roslan KA; Chandramohan P; Cheah YC; Leonard AO Med J Malaysia; 1998 Dec; 53(4):365-71. PubMed ID: 10971979 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. Malt UF; Nystad R; Bache T; Noren O; Sjaastad M; Solberg KO; Tønseth S; Zachariassen P; Maehlum E Br J Psychiatry; 1995 Mar; 166(3):374-7. PubMed ID: 7788130 [TBL] [Abstract][Full Text] [Related]
14. Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-centre study. Nygaard H; Bakke K; Brudvik E; Lien GK; Moe TJ; Elgen K Pharmatherapeutica; 1988; 5(3):152-8. PubMed ID: 2896359 [TBL] [Abstract][Full Text] [Related]
15. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales. Bobon D; Troisfontaines B; Kempeneers JL; Xhenseval B; Bourdouxhe S; Mirel J; Gilson H; Toussaint C; von Frenckell R; Pedersen V Acta Psychiatr Belg; 1986; 86(2):152-76. PubMed ID: 2873713 [TBL] [Abstract][Full Text] [Related]
16. Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients. Izmeth MG; Khan SY; Kumarajeewa DI; Shivanathan S; Veall RM; Wiley YV Pharmatherapeutica; 1988; 5(4):217-27. PubMed ID: 2902642 [TBL] [Abstract][Full Text] [Related]
17. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Aman MG; Gharabawi GM; J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046 [TBL] [Abstract][Full Text] [Related]
18. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Chouinard G; Safadi G; Beauclair L J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017 [TBL] [Abstract][Full Text] [Related]
19. Zuclopenthixol, melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway. Nygaard HA; Fuglum E; Elgen K Curr Med Res Opin; 1992; 12(10):615-22. PubMed ID: 1353014 [TBL] [Abstract][Full Text] [Related]
20. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial. Fernández-Mayoralas DM; Fernández-Jaén A; Muñoz-Jareño N; Calleja-Pérez B; Fernández-Perrone AL; Arribas SL Clin Neuropharmacol; 2012; 35(5):227-30. PubMed ID: 22935606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]